Network Pharmacology Strategy to Investigate the Pharmacological Mechanism of HuangQiXiXin Decoction on Cough Variant Asthma and Evidence‐Based Medicine Approach Validation

Abstract

Objective. To investigate the pharmacological mechanism of HuangQiXiXin decoction (HQXXD) on cough variant asthma (CVA) and validate the clinical curative effect. Methods. The active compounds and target genes of HQXXD were searched using TCMSP. CVA-related target genes were obtained using the GeneCards database. The active target genes of HQXXD were compared with the CVA-related target genes to identify candidate target genes of HQXXD acting on CVA. A medicine-compound-target network was constructed using Cytoscape 3.6.0 software, and a protein-protein interaction (PPI) network was constructed using the STRING database. Gene ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using RGUI3.6.1 and Cytoscape 3.6.0. We searched the main database for randomized controlled trials of HQXXD for CVA. We assessed the quality of the included studies using the Cochrane Reviewers’ Handbook. A meta-analysis of the clinical curative effect of HQXXD for CVA was conducted using the Cochrane Collaboration’s RevMan 5.3 software. Results. We screened out 48 active compounds and 217 active target genes of HQXXD from TCMSP. The 217 active target genes of HQXXD were compared with the 1481 CVA-related target genes, and 132 candidate target genes for HQXXD acting on CVA were identified. The medicine-compound-target network and PPI network were constructed, and the key compounds and key targets were selected. GO function enrichment and KEGG pathway enrichment analysis were performed. Meta-analysis showed that the total effective rate of the clinical curative effect was significantly higher in the experimental group than the control group. Conclusion. The pharmacological mechanism of HQXXD acting on CVA has been further determined, and the clinical curative effect of HQXXD on CVA is remarkable.

Construction of a potential microRNA and messenger RNA regulatory network of acute lung injury in mice

“…The RGUI 4.0.3 and org.Hs.eg.db packages were applied to obtain the entrezIDs of the candidate target genes. RGUI and the clusterProfiler package were used to perform GO function enrichment analysis, which included BP, MF and CC, as well as KEGG pathway enrichment analysis 36 , 37 .…”

Danggui Buxue Decoction Ameliorates Idiopathic Pulmonary Fibrosis through MicroRNA and Messenger RNA Regulatory Network

“…We used the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP; https://old.tcmsp-e.com/tcmsp.php ) to obtain the chemical compounds and their corresponding target genes in DGBXD (RA and RAS) [ 38 ]. Drug-likeness (DL) ≥ 0.18 and oral bioavailability (OB) ≥ 30% were established as thresholds to identify the active compounds, with reference to previous studies [ 26 , 39 ]. All human gene symbols were corrected to their official gene symbols with the aid of UniProt Knowledgebase ( https://www.uniprot.org/ ) [ 40 , 41 ].…”

Analysis of the Efficacy and Pharmacological Mechanisms of Action of Zhenren Yangzang Decoction on Ulcerative Colitis Using Meta-Analysis and Network Pharmacology

“…Oral bioavailability (OB) and drug-likeness (DL) are commonly used in network pharmacology to define active compounds. OB represents the rate the compound is absorbed into the body, and DL represents the degree to which a compound contains specific functional groups or has physical characteristics similar to existing drugs [ 16 ]. We used OB ≥ 30% and DL ≥ 0.18 to screen for the active compounds (the DLs of compounds in CC are generally low, and we, therefore, set DL ≥ 0.10 as the filter criteria) [ 17 ].…”